NCT05625633View on ClinicalTrials.gov

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Warts
Interventions
BIOLOGICAL

Human Papillomavirus 9-valent Vaccine, Recombinant

0.5-mL suspension of 9-valent Gardasil administered as intramuscular injection at weeks 0, 4, and 20

OTHER

Normal Saline

0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20

Trial Locations (2)

84107

RECRUITING

University of Utah Midvalley Health Center, Salt Lake City

84148

RECRUITING

VA Salt Lake City Health Care System, Salt Lake City

All Listed Sponsors
collaborator

University of Utah

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Western Institute for Veterans Research

OTHER